Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000244469 | SCV000303006 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001237017 | SCV001409764 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002338795 | SCV002643745 | uncertain significance | Cardiovascular phenotype | 2022-05-27 | criteria provided, single submitter | clinical testing | The p.V399M variant (also known as c.1195G>A), located in coding exon 9 of the JAG1 gene, results from a G to A substitution at nucleotide position 1195. The valine at codon 399 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |